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Histone deacetylase (HDAC) inhibitors have shown signiﬁcant activity in the treatment of cutaneous T-cell lymphomas (CTCL).
The epigenetic alterations of CTCL not only are limited to altered histone acetylation but also include aberrant DNA gene
methylation hence, the combination of an HDAC inhibitor with a DNA demethylating agent is a promising therapy to be tested.
Here we report a mycosis fungoides patient having a dramatic response to hydralazine and valproate, two repositioned drugs as
HDAC and DNA methylation inhibitors, respectively.
1.Introduction
Mycosis fungoides (MF) is a rare disease that represents the
most common type of primary CTCL, which is characterized
by a clonal proliferation of malignant lymphocytes in the
skin. Typically, the natural history of MF is indolent.
Symptoms of the disease may present for long periods, an
average of 2 to 10 years, as waxing and waning cutaneous
eruptions prior to biopsy conﬁrmation [1]. Currently, skin-
directed treatment regimens, like phototherapy and corti-
costeroids, are commonly used in early stages; while for
advanced diseases systemic treatments include bexarotene,
denileukin diftitox, lenalidomide, toll-like receptor agonists,
pralatrexate, bortezomib, as well as cytotoxic chemotherapy.
Curative modalities, however, have thus far proven elusive,
with the possible exception of patients with minimal disease
conﬁned to the skin [2]. Epigenetic therapy based on
DNA methyltransferase (DNMT) and HDAC inhibitors is at
present widely evaluated in a number of malignant diseases
[3]. CTCL has been found to overexpress several HDACs
which include HDAC1, HDAC2, and HDAC6 [4] and several
clinical trials have examined the sensitivity of CTCL to
HDAC inhibitors. Vorinostat, panobinostat, belinostat, and
romidepsin have all shown eﬃcacy in indolent and advanced
stages of CTCL in patients who have failed prior systemic
therapies. Vorinostat yields response rates of 25%–30% in
advanced stages (MF stage IIB–IVB) [5]. Belinostat has
shown eﬃcacy in a phase II clinical trial against recurrent
and refractory CTCL with PRs in two of eight patients with
MF [6]. Romidepsin has resulted in an overall response
rate of 31%, with PRs reported in plaque/patch and tumor
stages of MF [7]. Panobinostat has also demonstrated a
response rate in six out of 10 patients with advanced-stage
CTCL, with two CRs and four PRs [8]. Although objective
responses, that is, complete or partial, are not reached by
all CTCL patients, many still beneﬁt from treatment by2 Case Reports in Medicine
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Figure 1: The status of the disease before starting HV is shown in Figure 1(a), and after treatment in Figure 1(b).
achieving stable disease and/or pruritus relief [5–8]. On the
other hand, malignant T cells of patients with CTCL also
display widespread promoter hypermethylation associated
with inactivation of several tumor suppressor genes involved
in DNA repair, cell cycle, and apoptosis signaling pathways;
however, no clinical studies have been reported with DNMT
inhibitors in this neoplasia [9].
Hydralazine and magnesium valproate (HV) are DNMT
and HDAC inhibitors, respectively. Clinically, these drugs
decrease global DNA methylation and HDAC activity in
the peripheral blood of patients, as well as upregulation of
genes in primary breast cancer tumors [10]. Likewise, in
a pilot study these epigenetic drugs were able to overcome
chemotherapy resistance in refractory solid tumor patients
regardless of tumor type and chemotherapy schedule [11].
Overall, this information may suggest that HV could be an
eﬀective therapy for CTCL.
2.CaseReport
This 74-year-old female patient was seen in September
2007 with a three-month history of disseminated itching
cutaneous erythematous hyperpigmented plaques aﬀecting
the face, chest, and arms to then disseminate to most of body
surface except in palms, soles, and scalp. A skin biopsy was
reported as reticular erythematous mucinosis and treatment
was started with topical steroids and hydroxychloroquine
with no response. In December 2007 the treatment was
changed to thalidomide, again with no response. In April
2008 a new skin biopsy was reported as compatible with
Mycosis Fungoides by having an atypical CD4 lymphocytic
inﬁltrate. Extension studies which included cervical, tho-
racic, abdominal, and pelvic CT scan as well as a bone
marrow biopsy were negative so she was staged as IIIA.
Right after, she started treatment with oral methotrexate at
increasing doses starting at 10mg/m2 weekly up to 40mg/m2
until September 2008 when she achieved a maximum
response in the size and extension of plaques. However,
no improvement in itching was achieved. In October 2008
her lesions worsened aﬀecting almost 80% of body surface
plus the presence of ulcerated and nonulcerated nodules in
the scalp. By December 2008, she entered into a clinical
protocol with single agent enzastaurine. Nonetheless, after
the ﬁrst course of treatment she had progression with lesions
aﬀecting almost the totality of body surface area. In January
2009 after an extensive information and discussion with the
patient and her daughter, she accepted to receive hydralazine
and magnesium valproate in a compassive manner. Repre-
sentative pictures of the disease status at this point and after
treatment are shown in Figures 1(a) and 1(b).
The epigenetic therapy consisted on magnesium val-
proate at 30mg/Kg and hydralazine at a total daily dose
of 182mg as she was typed as rapid acetylator (slow-
acetylators receive a dose of 83mg/day, the acetylator
phenotype is performed with the sulfametazine test, where
patients take P.O. sulfametazine and urine is collected by 6
hours, then the ratio of acetylated/nonacetylated metabolites
is measured). These medications are formulated in slow-
release tablets. Within the next week she started to feel
decreasing in the severity of pruritus and decreasing in
size and erythema of plaques. After two weeks the patient
reported complete resolution of pruritus and there was
no need of taking gabapentin due to the disappearance
of neuropathic symptoms in both hands. In the ensuing
weeks the erythrodermia vanished only remaining a slightly
hyperpigmented skin in the previous diseased areas. This
dramatic response was however accompanied by side eﬀects.
Soon after starting medication the patient complained of
somnolence (which did not interfere with the normal-
life activities), fatigue, nausea, dysgeusia, anorexia, and
weight loss. In addition, the patient had dehydration and
a paradoxical hypertension which required antihypertensive
drugs. Most likely, both factors conditioned acute renal
failure (a maximum creatinine of 6.5mg/100mL which
required hospitalization for hydration and pharmacological
control of hypertension.) Ten days after, serum creatinine
returnedtonormal.Thisepisodeledtowithdrewhydralazine
and valproate. In March 2009 the patient continued taking
no epigenetic drugs and commenced again with pruritus
and mild erythrodermia in previously aﬀected areas, hence
valproate only was restarted and after three weeks the patientCase Reports in Medicine 3
became again asymptomatic. Currently, she remains free of
symptoms and the skin condition with no signs of active
disease at 14 months of treatment, except for a persistent but
decreasing dandruﬀ.
3. Discussion
The dramatic clinical response to the combination of
hydralazine and valproate is in line with the activity against
CTCL of HDAC inhibitors as drug class [5–8]. This result
is not unexpected as valproic acid has shown yet to be less
potent than other HDAC inhibitors to have remarkable anti-
tumor activity either alone or associated with chemotherapy
against a number of neoplasms, particularly hematological
ones [12–15]. On the other hand, hydralazine—a weak
nonnucleoside DNA methylation inhibitor [16] has shown
synergy with valproic acid in regard to gene reactivation
and antitumor eﬀects [17]. Though the activity of this
combination is limited to the present case, the response rate
seemed to occur faster than that achieved with vorinostat
which is reported to range from 3.6 to 21.9 weeks [5], this
may suggest that adding a DNA methylation inhibitor could
be advantageous by facilitating the reactivation of tumor
suppressorgenessilencedbyepigeneticmechanisms[9].This
concept has been widely proven in experimental systems
were both DNMTs and HDACs participate in the epigenetic
silencing of genes [18]. Nevertheless, this combination is not
devoid of side eﬀects. In previous studies with hydralazine
and valproate added to chemotherapy or chemoradiation,
the most frequent and signiﬁcant toxicity is hematological
followed by somnolence which usually is transient, as
well as fatigue and anorexia [10, 11]. Unexpectedly, the
patient presented paradoxical hypertension which in our
knowledge has not been reported with this agent or in
combination with valproate which was coincidental with
dehydration causing transient renal failure. Nevertheless,
because of the rapid response to the treatment, a tumor
lysis syndrome cannot be ruled out as the cause of the
transient renal failure. In conclusion, this case report is
illustrative on the activity of known drugs which have been
repositioned in cancer therapeutics [19, 20]. Currently, a
phase II trial with this combination is ongoing in CTCL.
If the activity and safety of this therapy is proven, it will
deﬁnitively be a great contribution for the management
of this neoplasia worldwide because at diﬀerence of the
other HDAC inhibitors which have been developed fol-
lowing the current approach of DDD (Drug Design &
Development) and have a prohibitive cost for many cancer
patients, repositioned old drugs as a rule will have lower
price.
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